News, trends, and stories from the synthetic biology industry
Hi , This week, we bring you bio-batteries harnessing the power of DNA, the importance of technological sovereignty, Synthetic Biology Clubhouse breaking news, and the latest Biopharma Conference speakers:
Join us TODAY at 8 am PST for the Synthetic Biology Breaking News conversation on Clubhouse. Speakers include:
Darko Mandich, CEO of MeliBio, who will be talking about their $850,000 pre-seed round funding to make real honey without bees.
Jennifer Holmgren, CEO of LanzaTech, who
will be discussing Shell’s investment in LanzaJet to speed up deliveries of its sustainable aviation fuel.
John Cumbers for Forbes
Global Investor Hermann Hauser Warns: Your Country May Be About To Lose Technological Sovereignty Renowned investor and close friend of John Cumbers, Hermann Hauser, thinks we have a serious problem: If the core tech platforms for building innovation are privatized and sold, we have lost the opportunity for a lifetime of innovation. Read John’s interview with Hermann Hauser for Forbes.
Meet The Company Reprogramming The Future Of Synthetic Biology The first two decades of synthetic biology were ruled by
microbes— practically engineering mammalian cells was simply not possible. But now, bit.bio is giving cells new identities through its platform, opti-ox, and transforming what’s possible in synthetic biology.
SynBioBeta In-Depth
Living Power: This Bio-Battery Is
Harnessing the Power of DNA Synthetic biology innovations could aid the transition to a more energy-efficient future. One of these innovations is the bio-battery, a biofuel cell powered by enzymes that breaks down organic compounds for fuel. A partnership between Touchlight Genetics and the Minteer Research Group at the University of Utah is taking a new approach to bio-batteries with DNA.
Biopharma Day
Here are the latest Biopharma Day speakers! Learn key insights into how 2020 transformed the Biopharma Industry and what new technologies and diagnostic capabilities are continuing to accelerate drug
discovery.Be sure to get your tickets now!
Funding news
Congratulations to Benchling for raising $200 million! The company developed a cloud-based informatics platform to design DNA, collaborate on experiments, automate data capture, and manage research workflows with the aim of bringing products to market faster.
Outpace Bio, a spinout from Lyell Immunopharma, has landed $30 million in Series A funding to design new proteins that solve problems in cell
therapies.
Mission Barns, a company on a quest for ‘kosher bacon’, raised $24 million for its lab-grown fat.
Science News
Senti Biosciences announced a collaboration with Spark Therapeutics to apply Senti Bio’s gene circuit technology to the development of gene therapies directed toward specific cell types in the central nervous system (CNS), eye or liver.
An on-off switch for gene editing: Researchers describe a new gene editing technology called CRISPRoff that allows researchers to control gene expression with high specificity while leaving the sequence of the DNA unchanged.
